{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:34:52Z","timestamp":1792128892250,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-023-04332-z","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T05:03:38Z","timestamp":1677042218000},"page":"3195-3203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-9134","authenticated-orcid":false,"given":"G\u00e9raldine","family":"Pignot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Lebacle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Chamouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lechevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Tillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Waeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Monges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Doisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Duperron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"5","key":"4332_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","volume":"49","author":"JA Witjes","year":"2006","unstructured":"Witjes JA (2006) Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49(5):790\u2013797. https:\/\/doi.org\/10.1016\/j.eururo.2006.01.017","journal-title":"Eur Urol"},{"issue":"1","key":"4332_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ). Eur Urol 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"issue":"4","key":"4332_CR3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","volume":"173","author":"AG van der Heijden","year":"2015","unstructured":"van der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA (2015) Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173(4):1375\u20131380. https:\/\/doi.org\/10.1097\/01.ju.0000146274.85012.e1","journal-title":"J Urol"},{"issue":"6","key":"4332_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJH Arends","year":"2016","unstructured":"Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non\u2013muscle-invasive bladder cancer. Eur Urol 69(6):1046\u20131052. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.006","journal-title":"Eur Urol"},{"issue":"1","key":"4332_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L, Devall AJ, Loubi\u00e8re LS, Pope AM et al (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Gu\u00e9rin therapy (HYMN): a phase III, open-label. Randomised Controlled Trial Eur Urol 75(1):63\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.005","journal-title":"Randomised Controlled Trial Eur Urol"},{"issue":"4","key":"4332_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3109\/02656736.2016.1142618","volume":"32","author":"A Sousa","year":"2016","unstructured":"Sousa A, Pi\u00f1eiro I, Rodr\u00edguez S, Aparici V, Monserrat V, Neira P et al (2016) Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate\u2013high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia 32(4):374\u2013380. https:\/\/doi.org\/10.3109\/02656736.2016.1142618","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"4332_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/blc-180191","volume":"4","author":"JJ de Jong","year":"2018","unstructured":"de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL (2018) Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer 4(4):395\u2013401. https:\/\/doi.org\/10.3233\/blc-180191","journal-title":"Bladder Cancer"},{"issue":"22","key":"4332_CR8","doi-asserted-by":"publisher","first-page":"02552","DOI":"10.1016\/j.eururo.2022.08.003","volume":"S0302\u20132838","author":"WS Tan","year":"2022","unstructured":"Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P et al (2022) Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label. Randomised Controlled Trial Eur Urol S0302\u20132838(22):02552. https:\/\/doi.org\/10.1016\/j.eururo.2022.08.003","journal-title":"Randomised Controlled Trial Eur Urol"},{"issue":"16","key":"4332_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/jco.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A, Palou J, Lamm DL, Brausi M et al (2016) Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 34(16):1935\u20131944. https:\/\/doi.org\/10.1200\/jco.2015.64.4070","journal-title":"J Clin Oncol"},{"issue":"14","key":"4332_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.purol.2016.09.057","volume":"6","author":"J Irani","year":"2016","unstructured":"Irani J (2016) Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy. Prog Urol 6(14):860\u2013864. https:\/\/doi.org\/10.1016\/j.purol.2016.09.057","journal-title":"Prog Urol"},{"issue":"3","key":"4332_CR11","doi-asserted-by":"publisher","first-page":"195.e1","DOI":"10.1016\/j.urolonc.2020.09.006","volume":"39","author":"FX Nouhaud","year":"2021","unstructured":"Nouhaud FX, Chakroun M, Lenormand C, Ouzaid I, Peyronnet B, Gryn A et al (2021) Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: results from a large multicenter study. Urol Oncol 39(3):195.e1-195.e6. https:\/\/doi.org\/10.1016\/j.urolonc.2020.09.006","journal-title":"Urol Oncol"},{"issue":"7","key":"4332_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M et al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22(7):919\u2013930. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9","journal-title":"Lancet Oncol"},{"issue":"9","key":"4332_CR13","doi-asserted-by":"publisher","first-page":"409.e1","DOI":"10.1016\/j.urolonc.2022.02.003","volume":"40","author":"HA Garc\u00eda-Perdomo","year":"2022","unstructured":"Garc\u00eda-Perdomo HA, S\u00e1nchez AL, Spiess PE (2022) Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review. Urol Oncol 40(9):409.e1-409.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.003","journal-title":"Urol Oncol"},{"issue":"1","key":"4332_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM et al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117. https:\/\/doi.org\/10.1016\/S1470-2045(20)30540-4","journal-title":"Lancet Oncol"},{"issue":"3","key":"4332_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/MOU.0000000000000863","volume":"31","author":"VT Packiam","year":"2021","unstructured":"Packiam VT, Richards J, Schmautz M, Heidenreich A, Boorjian SA (2021) The current landscape of salvage therapies for patients with bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol 31(3):178\u2013187. https:\/\/doi.org\/10.1097\/MOU.0000000000000863","journal-title":"Curr Opin Urol"},{"issue":"12","key":"4332_CR16","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","volume":"27","author":"JA Foltz","year":"2021","unstructured":"Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E et al (2021) Phase I trial of N-803, an Il15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma. Clin Cancer Res 27(12):3339\u20133350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4575","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4332_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","volume":"3","author":"AM Kamat","year":"2020","unstructured":"Kamat AM, Lerner SP, O\u2019Donnell M, Georgieva MV, Yang M, Inman BA et al (2020) Evidence-based assessment of current and emerging bladder-sparing therapies for non\u2013muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol 3(3):318\u2013340. https:\/\/doi.org\/10.1016\/j.euo.2020.02.006","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"4332_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52(4):1123\u20131129. https:\/\/doi.org\/10.1016\/j.eururo.2007.02.063","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04332-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04332-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04332-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T04:06:23Z","timestamp":1699416383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04332-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["4332"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04332-z","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest related to the subject of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study design was approved by the appropriate ethics review board (approved protocol number: THERMO-MMC-IPC 2019\u2013019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Retrospective collection of data\u2014Study submitted and approved by the ethics committee of Institut Paoli-Calmettes (THERMO-MMC).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}